NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ZVRA

Zevra Therapeutics Inc

Jul 03 • 04:00PM ET

9.74

Dollar change +0.33
Percentage change 3.51	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX GILD ALNY REGN BMRN IONS NBIX SRPT EXEL BLUE

| Held by: VTI IWM VXF IWO IBB VTWO SURI IWC ITOT XPH

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.89	Insider Own	1.18%	Shs Outstand	54.68M	Perf Week	4.96%
Market Cap	532.58M	Forward P/E	14.90	EPS next Y	0.65	Insider Trans	-16.77%	Shs Float	54.03M	Perf Month	9.81%
Enterprise Value	531.79M	PEG	-	EPS next Q	-0.09	Inst Own	65.35%	Short Float	8.72%	Perf Quarter	27.15%
Income	-91.99M	P/S	13.12	EPS this Y	88.27%	Inst Trans	6.68%	Short Ratio	8.07	Perf Half Y	18.64%
Sales	40.59M	P/B	12.98	EPS next Y	344.39%	ROA	-56.78%	Short Interest	4.71M	Perf YTD	16.79%
Book/sh	0.75	P/C	8.50	EPS next 5Y	-	ROE	-204.78%	52W High	9.76 -0.20%	Perf Year	98.78%
Cash/sh	1.15	P/FCF	-	EPS past 3/5Y	-2.57% 29.64%	ROIC	-89.95%	52W Low	4.20 131.90%	Perf 3Y	108.12%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-6.24% 12.96%	Gross Margin	51.37%	Volatility	5.23% 3.99%	Perf 5Y	100.02%
Dividend TTM	-	EV/Sales	13.10	EPS Y/Y TTM	-40.06%	Oper. Margin	-177.09%	ATR (14)	0.39	Perf 10Y	-96.88%
Dividend Ex-Date	-	Quick Ratio	2.93	Sales Y/Y TTM	44.92%	Profit Margin	-226.64%	RSI (14)	65.74	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.02	EPS Q/Q	85.60%	SMA20	6.36%	Beta	1.85	Target Price	23.29
Payout	-	Debt/Eq	1.51	Sales Q/Q	495.65%	SMA50	14.45%	Rel Volume	2.02	Prev Close	9.41
Employees	59	LT Debt/Eq	1.49	Earnings	May 13 AMC	SMA200	18.92%	Avg Volume	583.61K	Price	9.74
IPO	Apr 16, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	66.92% 20.62%	Trades		Volume	1,176,785	Change	3.51%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-02-25	Initiated	H.C. Wainwright	Buy	$26
Jan-08-25	Resumed	Cantor Fitzgerald	Overweight	$25
Oct-07-24	Initiated	Guggenheim	Buy	$20
Sep-24-24	Reiterated	Maxim Group	Buy	$18 → $25
Sep-24-24	Initiated	JMP Securities	Mkt Outperform	$17
Apr-02-24	Reiterated	Maxim Group	Buy	$12 → $18
Mar-12-24	Initiated	William Blair	Outperform
Mar-17-23	Initiated	Maxim Group	Buy	$12

Jul-03-25 08:19AM	Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last? (Zacks)
May-29-25 04:35PM	Zevra Announces Final Results of 2025 Annual Meeting of Stockholders (GlobeNewswire)
May-27-25 01:03PM	Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT (Insider Monkey)
May-21-25 07:30AM	All Three Leading Proxy Advisory Firms - ISS, Glass Lewis, and Egan-Jones - Recommend Zevra Stockholders Vote FOR the Company's Director Nominees (GlobeNewswire)
May-14-25 10:53AM	Q1 2025 Zevra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:15AM	Loading…
03:15AM	Zevra Therapeutics Inc (ZVRA) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges (GuruFocus.com)
May-13-25 05:20PM	Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:20PM	Zevra Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Zevra Reports First Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
May-12-25 09:33AM	Zevra Therapeutics Inc (ZVRA) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-08-25 08:20AM	Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-06-25 07:30AM	Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call (GlobeNewswire) -7.50%
May-01-25 04:05PM	Zevra Therapeutics to Participate in the Citizens Life Science Conference (GlobeNewswire)
Apr-21-25 07:22AM	Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders (GlobeNewswire)
Apr-17-25 07:30AM	Zevra Announces Publication of MIPLYFFA Mechanism of Action Manuscript in Molecular Genetics and Metabolism (GlobeNewswire)
12:24AM	Loading…
Apr-08-25 12:24AM	XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist (Seeking Alpha) -6.52%
Apr-07-25 07:30AM	Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million (GlobeNewswire)
Apr-03-25 06:38AM	Zevra Therapeutics: Mixed Feelings On Miplyffa Approval (Seeking Alpha)
Mar-31-25 04:12PM	Zevra Therapeutics Files Preliminary Proxy (GlobeNewswire)
Mar-12-25 12:31PM	Q4 2024 Zevra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:06AM	Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Mar-11-25 06:15PM	Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:22PM	Zevra Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Zevra Reports Full Year 2024 and Fourth Quarter Financial Results (GlobeNewswire)
Feb-28-25 07:30AM	Zevra Launches New Disease State Awareness Campaign, 'Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C (GlobeNewswire)
06:40AM	Praxis hits trial setback; Bristol Myers lays off staff in New Jersey (BioPharma Dive)
Feb-27-25 06:16PM	Zevra sells priority review voucher for $150m to support drug launches (Pharmaceutical Technology) +5.41%
07:30AM	Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million (GlobeNewswire)
Feb-26-25 09:46AM	Zevra to Report 2024 Fourth Quarter and Full Year Financial Results (GlobeNewswire)
Feb-24-25 04:02PM	Zevra to Participate at Upcoming Investor Conferences (GlobeNewswire)
07:30AM	Loading…
Jan-30-25 07:30AM	Zevra Therapeutics to Present at the 21st Annual WORLDSymposium (GlobeNewswire)
Jan-29-25 04:05PM	Zevra Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Dec-17-24 07:30AM	Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024 (GlobeNewswire)
Dec-09-24 02:48AM	A drug for fewer than 1,000 patients? Awareness and diagnosis are key. (Pharma Voice)
Dec-06-24 05:00PM	Zevra Therapeutics Announces Organizational Changes (GlobeNewswire)
Nov-26-24 07:30AM	Zevra Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-23-24 06:32AM	Zevra Therapeutics Launches MIPLYFFA for Niemann-Pick Disease (TipRanks)
Nov-21-24 04:51PM	Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA (arimoclomol) for Treatment of Niemann-Pick Disease Type C (GlobeNewswire)
Nov-13-24 02:17AM	Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... (GuruFocus.com)
Nov-12-24 06:00PM	Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:55PM	Zevra Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Nov-11-24 04:36PM	Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting (GlobeNewswire)
07:15AM	Zevra Therapeutics Inc (ZVRA) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-06-24 07:30AM	Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13 (GlobeNewswire)
Oct-31-24 07:30AM	Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024 (GlobeNewswire)
Oct-29-24 10:01AM	Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline (Zacks)
Oct-10-24 07:30AM	Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC (GlobeNewswire) -6.49%
Oct-09-24 06:19PM	Zevra Therapeutics Inc (ZVRA) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
09:00AM	NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders (GlobeNewswire)
Sep-25-24 06:22AM	Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last? (Zacks) -8.77%
Sep-24-24 07:30AM	Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 (GlobeNewswire) +9.10%
Sep-23-24 04:12AM	FDA approves Zevra Therapeutics Miplyffa for Niemann-Pick disease (Pharmaceutical Technology) -5.96%
Sep-20-24 01:27PM	Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease (Benzinga)
12:08PM	Zevra Therapeutics' MIPLYFFA (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C (GlobeNewswire)
Sep-06-24 08:30AM	Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium (GlobeNewswire)
Aug-29-24 07:30AM	Zevra Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 05:30PM	Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:26PM	Zevra Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Aug-09-24 12:00AM	Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire) -10.55%
Aug-08-24 04:01PM	Zevra Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Aug-07-24 09:34AM	Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth Conference (GlobeNewswire) -8.12%
Aug-06-24 10:00AM	Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline (Zacks)
Aug-05-24 11:13AM	Zevra wins FDA panel backing for previously rejected arimoclomol (Pharmaceutical Technology) +25.08%
Aug-02-24 05:50PM	FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C (GlobeNewswire)
Jul-30-24 08:38AM	Zevra Therapeutics to Report Second Quarter 2024 Financial Results (GlobeNewswire) -5.82%
Jul-10-24 03:04PM	Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug (Zacks)
08:24AM	Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains? (Zacks)
07:48AM	AbbVie names new R&D head; Arcutis eczema cream approved (BioPharma Dive)
Jul-09-24 03:27PM	FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base (Benzinga) +21.94%
09:00AM	Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C (GlobeNewswire)
Jun-25-24 07:30AM	Zevra Therapeutics Expands Executive Leadership Team (GlobeNewswire)
Jun-18-24 07:30AM	Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders (PR Newswire)
Jun-03-24 11:00AM	Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting (GlobeNewswire)
May-09-24 12:24PM	Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:30AM	Zevra Therapeutics to Participate at Upcoming Investor Events (GlobeNewswire)
03:03AM	Zevra Therapeutics Inc (ZVRA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-08-24 11:57AM	ZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:12AM	Zevra Therapeutics Inc (ZVRA) Q1 2024 Earnings: Misses EPS Estimates, Revenue Consistent with ... (GuruFocus.com)
08:15AM	Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:23AM	Zevra Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
May-01-24 07:30AM	Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024 (GlobeNewswire)
Apr-29-24 07:30AM	Zevra Therapeutics' President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024 (GlobeNewswire)
Apr-15-24 05:01PM	Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting (GlobeNewswire)
Apr-10-24 07:30AM	Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility (GlobeNewswire)
Apr-01-24 12:46PM	Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcript (Insider Monkey) -11.03%
Mar-29-24 12:07PM	Q4 2023 Zevra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 09:52PM	ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -11.03%
06:11PM	Zevra Therapeutics Inc (ZVRA) Earnings: A Mixed Bag Against Analyst Estimates with Significant ... (GuruFocus.com)
04:53PM	Zevra Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:32PM	Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates (GlobeNewswire)
Mar-26-24 04:30PM	Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia (GlobeNewswire)
Mar-25-24 04:30PM	Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-24 10:00AM	Will Zevra Therapeutics (ZVRA) Report Negative Earnings Next Week? What You Should Know (Zacks)
Mar-18-24 07:30AM	Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024 (GlobeNewswire)
Mar-07-24 11:56AM	Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-04-24 07:30AM	Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C (GlobeNewswire) -12.15%
Feb-28-24 07:30AM	Zevra Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thompson Rahsaan	Chief Legal & Compliance	Jun 26 '25	Sale	9.21	24,000	221,004	42,666	Jun 30 05:02 PM
RAHSAAN THOMPSON	Officer	Jun 26 '25	Proposed Sale	9.33	24,000	223,920		Jun 26 04:25 PM
Watton Corey Michael	Director	Mar 28 '25	Buy	7.84	300	2,352	1,800	Mar 31 08:05 PM
Bode John B	Director	Mar 19 '25	Buy	7.96	10,000	79,624	40,000	Mar 21 04:06 PM
Sangiovanni Timothy J.	SVP, Finance & Corp Controller	Feb 13 '25	Sale	7.86	3,000	23,588	16,341	Feb 14 05:57 PM
Schafer Joshua	CCO & EVP, Bus. Development	Feb 13 '25	Sale	7.86	10,500	82,527	29,486	Feb 14 05:55 PM
Clifton R. LaDuane	CFO & Treasurer	Feb 13 '25	Sale	7.86	11,000	86,471	51,361	Feb 14 05:55 PM
McFarlane Neil F.	President and CEO	Feb 13 '25	Sale	7.86	61,273	481,428	222,060	Feb 14 05:54 PM
McFarlane Neil F.	President and CEO	Feb 14 '25	Sale	8.05	30,544	245,962	191,516	Feb 14 05:54 PM
NEIL F MCFARLANE	Director	Feb 13 '25	Proposed Sale	7.72	91,817	708,827		Feb 13 04:38 PM
R. LADUANE CLIFTON	Officer	Feb 13 '25	Proposed Sale	7.72	11,000	84,920		Feb 13 04:29 PM
Timothy Sangiovanni	Officer	Feb 13 '25	Proposed Sale	7.72	3,000	23,160		Feb 13 04:29 PM
Joshua Schafer	Officer	Feb 13 '25	Proposed Sale	7.72	10,500	81,060		Feb 13 04:28 PM
Watton Corey Michael	Director	Oct 11 '24	Buy	7.92	500	3,958	1,500	Oct 16 04:46 PM
Clifton R. LaDuane	CFO & Treasurer	Jul 17 '24	Buy	6.77	2,000	13,540	18,469	Jul 17 05:54 PM
Anderson Thomas	Director	Jul 16 '24	Buy	6.81	10,000	68,065	20,000	Jul 16 04:39 PM
Bode John B	Director	Jul 12 '24	Buy	5.87	10,000	58,661	30,000	Jul 15 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZVRA

Zevra Therapeutics Inc

Upgrade your FINVIZ experience